RxDoctor Payments Data

Robert Lynch, MD

Family Medicine · Mount Dora, FLNPI 1841293198

Payments from drug & device makers

$2,115in general payments, 2019–2025

Across 112 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$315
  • Novo Nordisk$242
  • Amgen$229
  • Johnson & Johnson$216
  • Pfizer$191
  • Amarin Pharma, Inc.$150
  • plus $771 from 22 others

What the payments were for

  • Food & beverage$2,115100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,115 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$40,370
Medicare patients
157
Services billed
618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$85,300
JanuviaSitagliptin Phosphate77$55,983
JardianceEmpagliflozin18$28,801
XareltoRivaroxaban26$21,527
Repatha SyringeEvolocumab28$14,625
MyrbetriqMirabegron22$12,255
JanumetSitagliptin Phos/Metformin Hcl11$10,009
Tresiba Flextouch U-100Insulin Degludec14$8,765
Breo ElliptaFluticasone/Vilanterol15$8,367
SymbicortBudesonide/Formoterol Fumarate19$7,432
LantusInsulin Glargine,hum.Rec.Anlog31$6,910
Gabapentin272$6,573
Duloxetine Hcl174$6,052
Celecoxib74$6,045
Azithromycin204$5,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$191$85,30072 claims
MerckJanuvia, Janumet$18$65,99288 claims
Boehringer IngelheimJardiance$58$28,80118 claims
Johnson & JohnsonXarelto$216$21,52726 claims
Astellas Pharma US IncMyrbetriq$57$12,25522 claims
GSKBreo Ellipta$103$8,36715 claims
AstraZenecaSymbicort$315$7,43219 claims
Novo NordiskNovolog$242$2,49012 claims
AbbVieSynthroid$41$1,55416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Mount Dora

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →